Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02046200 · ClinicalTrials.gov registry record · Phase 1
Development of Ivermectin for Alcohol Use Disorders
A Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02046200 is a Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 11 participants.
The verdict
NCT02046200, a Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Current pharmacotherapies for alcohol use disorders (AUDs) have limited efficacy. Thus, the development of effective treatments for AUDs represents an important public health objective. Repositioning, i.e. using existing approved drugs for other indications, represents a fast and economically feasible approach for drug development. Ivermectin (IVM) is an FDA-approved antiparasitic medication that can significantly reduce alcohol intake in mice, suggesting that it may be useful in the treatment of AUDs in humans. The goal of this project is to provide key clinical evidence that IVM can be repositioned as a novel therapeutic agent to treat AUDs.
Interventions
- DRUG Placebo
- DRUG Ivermectin
- DRUG Alcohol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02046200
The ClinicalTrials.gov registry entry for NCT02046200 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02046200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02046200 about?
NCT02046200 is a clinical study titled "Development of Ivermectin for Alcohol Use Disorders". Current pharmacotherapies for alcohol use disorders (AUDs) have limited efficacy. Thus, the development of effective treatments for AUDs represents an important public health objective. Repositioning, i.e. using existing approved drugs for other indications, represents a fast and economically feasib...
What is the current status of trial NCT02046200?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2014-02. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02046200?
The interventions under investigation include: Placebo (DRUG), Ivermectin (DRUG), Alcohol (DRUG).
Who is sponsoring clinical trial NCT02046200?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.